Shiloh
Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2019/02/stewardship-resistance-scan-feb-01-2019
Stewardship / Resistance Scan for Feb 01, 2019
Animal stewardship partnership; Antibiotic pipeline details; New PACCARB members
Filed Under:
Antimicrobial Stewardship
[h=3]Public-private effort launched to boost animal antimicrobial stewardship[/h] The Foundation for Food and Agriculture Research (FFAR) this week announced a $15 million investment in the launch of the International Consortium for Antimicrobial Stewardship in Agriculture (ICASA), a public-private partnership to advance research on antimicrobial stewardship in animal agriculture and improve animal health and welfare.
ICASA was established "to accelerate innovation and improve antibiotic stewardship by building the cross-sector partnerships critical to making advances on a broad scale," FFAR said in a news release. ICASA scientists will field-test new technologies and management practices. Ultimately, the consortium aims to publish data that improve animal health and welfare and promote responsible use of antibiotics, FFAR said.
The consortium includes three of the world's largest meat companies, along with two livestock associations that together represent more than 85,000 producers. Collectively, ICASA member organizations represent about 40% of all beef cattle sold in the United States.
ICASA members are matching FFAR's initial $7.5 million investment. ICASA projects will initially focus on animal health issues that drive antimicrobial use in beef and pork. ICASA will also support cross-species projects focused on animal health and welfare monitoring, with the aim of boosting knowledge of diseases that drive antibiotic use.
"ICASA has the potential to have extraordinary impact. The collaborative framework brings together exceptional expertise and significant resources to tackle major challenges in livestock production. Working together is critical to improving animal health and welfare and preserving the efficacy of antibiotics for both animals and people," Timothy Kurt, DVM, PhD, scientific program director at FFAR, said in the release.
FFAR, based in Washington, D.C., was established in 2014 as part of the Agriculture Act (Farm Bill).
Jan 30 FFAR news release
ICASA home page
[h=3]IDSA notes antibiotic development progress, concerns for future[/h] In an update to their 2013 antibiotic pipeline status report, experts from the Infectious Diseases Society of American (IDSA) today note that the number of new antibiotics approved by the US Food and Drug Administration (FDA) has reversed its previous decline. But they worry that, if the goal of 20 new antibiotics by 2020 (20 x '20) is achieved, it could mark the pinnacle of antibiotic development for years to come, according to their paper in Clinical Infectious Diseases.
The scientists performed an in-depth review of the literature and clinicaltrials.gov to identify new antibiotic drug candidates in the development pipeline, as well as FDA-approved agents since 2012.
They note that the FDA approved 7 new antibiotics in 2013 through 2017, compared with 6 in 2003 through 2007 and 2 in 2008 through 2012. Altogether, they detail 16 drugs that target gram-negative organisms and 11 that target gram-positive, lower respiratory tract, or other organisms that are in phase 2 or 3 clinical trials or approved by the FDA as of Sep 18, 2018. In addition, they note that 9 intravenous antibiotics targeting gram-negative bacteria are in early clinical development.
The authors write, "Since our 2013 pipeline status report, the number of new antibiotics annually approved for marketing in the US has reversed its previous decline, likely influenced by new financial incentives and increased regulatory flexibility."
But they add, "Although our survey demonstrates progress in development of new antibacterial drugs that target infections caused by resistant bacterial pathogens, the majority of recently approved agents have been modifications of existing chemical classes of antibiotics, rather than new chemical classes." They also point out that many drug companies are abandoning antibiotics.
The IDSA experts conclude, "Unfortunately, if 20 x '20 is achieved due to efforts embarked upon in decades past, it could mark the apex of antibiotic drug development for years to come." They advocate for increased government and industry efforts and durable solutions to regulatory and financial hurdles.
Feb 1 Clin Infect Dis report
[h=3]Presidential advisory council on resistance appoints new voting members[/h] The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) announced this week that it has appointed four new voting members to serve on the council.
The new members are Paula Fedorka-Cray, PhD, MS, a professor of population health and pathobiology at North Carolina State University College of Veterinary Medicine; Christine Ginocchio, PhD, MT, vice president of global medical affairs for bioMerieux and Biofire Diagnostics; Locke Karriker, DVM, MS, professor of veterinary medicine at Iowa State University College of Veterinary Medicine; and David White, PhD, MS, associate dean for research at the University of Tennessee Institute of Agriculture. Each member was appointed to a 4-year term.
Established in 2014, PACCARB provides advice, information, and recommendations to the Assistant Secretary for Health on programs and policies that support US government activities related to antibiotic resistance. The council meets at least twice a year.
Jan 29 PACCARB announcement
Stewardship / Resistance Scan for Feb 01, 2019
Animal stewardship partnership; Antibiotic pipeline details; New PACCARB members
Filed Under:
Antimicrobial Stewardship
[h=3]Public-private effort launched to boost animal antimicrobial stewardship[/h] The Foundation for Food and Agriculture Research (FFAR) this week announced a $15 million investment in the launch of the International Consortium for Antimicrobial Stewardship in Agriculture (ICASA), a public-private partnership to advance research on antimicrobial stewardship in animal agriculture and improve animal health and welfare.
ICASA was established "to accelerate innovation and improve antibiotic stewardship by building the cross-sector partnerships critical to making advances on a broad scale," FFAR said in a news release. ICASA scientists will field-test new technologies and management practices. Ultimately, the consortium aims to publish data that improve animal health and welfare and promote responsible use of antibiotics, FFAR said.
The consortium includes three of the world's largest meat companies, along with two livestock associations that together represent more than 85,000 producers. Collectively, ICASA member organizations represent about 40% of all beef cattle sold in the United States.
ICASA members are matching FFAR's initial $7.5 million investment. ICASA projects will initially focus on animal health issues that drive antimicrobial use in beef and pork. ICASA will also support cross-species projects focused on animal health and welfare monitoring, with the aim of boosting knowledge of diseases that drive antibiotic use.
"ICASA has the potential to have extraordinary impact. The collaborative framework brings together exceptional expertise and significant resources to tackle major challenges in livestock production. Working together is critical to improving animal health and welfare and preserving the efficacy of antibiotics for both animals and people," Timothy Kurt, DVM, PhD, scientific program director at FFAR, said in the release.
FFAR, based in Washington, D.C., was established in 2014 as part of the Agriculture Act (Farm Bill).
Jan 30 FFAR news release
ICASA home page
[h=3]IDSA notes antibiotic development progress, concerns for future[/h] In an update to their 2013 antibiotic pipeline status report, experts from the Infectious Diseases Society of American (IDSA) today note that the number of new antibiotics approved by the US Food and Drug Administration (FDA) has reversed its previous decline. But they worry that, if the goal of 20 new antibiotics by 2020 (20 x '20) is achieved, it could mark the pinnacle of antibiotic development for years to come, according to their paper in Clinical Infectious Diseases.
The scientists performed an in-depth review of the literature and clinicaltrials.gov to identify new antibiotic drug candidates in the development pipeline, as well as FDA-approved agents since 2012.
They note that the FDA approved 7 new antibiotics in 2013 through 2017, compared with 6 in 2003 through 2007 and 2 in 2008 through 2012. Altogether, they detail 16 drugs that target gram-negative organisms and 11 that target gram-positive, lower respiratory tract, or other organisms that are in phase 2 or 3 clinical trials or approved by the FDA as of Sep 18, 2018. In addition, they note that 9 intravenous antibiotics targeting gram-negative bacteria are in early clinical development.
The authors write, "Since our 2013 pipeline status report, the number of new antibiotics annually approved for marketing in the US has reversed its previous decline, likely influenced by new financial incentives and increased regulatory flexibility."
But they add, "Although our survey demonstrates progress in development of new antibacterial drugs that target infections caused by resistant bacterial pathogens, the majority of recently approved agents have been modifications of existing chemical classes of antibiotics, rather than new chemical classes." They also point out that many drug companies are abandoning antibiotics.
The IDSA experts conclude, "Unfortunately, if 20 x '20 is achieved due to efforts embarked upon in decades past, it could mark the apex of antibiotic drug development for years to come." They advocate for increased government and industry efforts and durable solutions to regulatory and financial hurdles.
Feb 1 Clin Infect Dis report
[h=3]Presidential advisory council on resistance appoints new voting members[/h] The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) announced this week that it has appointed four new voting members to serve on the council.
The new members are Paula Fedorka-Cray, PhD, MS, a professor of population health and pathobiology at North Carolina State University College of Veterinary Medicine; Christine Ginocchio, PhD, MT, vice president of global medical affairs for bioMerieux and Biofire Diagnostics; Locke Karriker, DVM, MS, professor of veterinary medicine at Iowa State University College of Veterinary Medicine; and David White, PhD, MS, associate dean for research at the University of Tennessee Institute of Agriculture. Each member was appointed to a 4-year term.
Established in 2014, PACCARB provides advice, information, and recommendations to the Assistant Secretary for Health on programs and policies that support US government activities related to antibiotic resistance. The council meets at least twice a year.
Jan 29 PACCARB announcement